NCT00412477View on ClinicalTrials.gov

A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 20, 2004

Primary Completion Date

March 13, 2006

Study Completion Date

November 1, 2006

Conditions
HIV Infections
Interventions
BIOLOGICAL

HIV LFn-p24

HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.

Trial Locations (1)

20850

Vaccine Clinical Research Center, Rockville

All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT00412477 - A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine | Biotech Hunter | Biotech Hunter